- Home
- CISS vs BCDA Comparison
CISS vs BCDA Comparison
Compare CISS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- BCDA
- Stock Information
- Founded
- CISS 2022
- BCDA N/A
- Country
- CISS Greece
- BCDA United States
- Employees
- CISS N/A
- BCDA N/A
- Industry
- CISS Marine Transportation
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- BCDA Health Care
- Exchange
- CISS Nasdaq
- BCDA Nasdaq
- Market Cap
- CISS 8.1M
- BCDA 7.9M
- IPO Year
- CISS N/A
- BCDA N/A
- Fundamental
- Price
- CISS $0.64
- BCDA $2.05
- Analyst Decision
- CISS
- BCDA Strong Buy
- Analyst Count
- CISS 0
- BCDA 1
- Target Price
- CISS N/A
- BCDA $25.00
- AVG Volume (30 Days)
- CISS 253.9K
- BCDA 31.3K
- Earning Date
- CISS 11-18-2024
- BCDA 11-13-2024
- Dividend Yield
- CISS N/A
- BCDA N/A
- EPS Growth
- CISS N/A
- BCDA N/A
- EPS
- CISS N/A
- BCDA N/A
- Revenue
- CISS $46,661,732.00
- BCDA $71,000.00
- Revenue This Year
- CISS N/A
- BCDA N/A
- Revenue Next Year
- CISS N/A
- BCDA N/A
- P/E Ratio
- CISS N/A
- BCDA N/A
- Revenue Growth
- CISS 491.48
- BCDA N/A
- 52 Week Low
- CISS $0.61
- BCDA $1.84
- 52 Week High
- CISS $68.50
- BCDA $10.80
- Technical
- Relative Strength Index (RSI)
- CISS 24.09
- BCDA 42.16
- Support Level
- CISS $0.67
- BCDA $2.00
- Resistance Level
- CISS $0.78
- BCDA $2.14
- Average True Range (ATR)
- CISS 0.05
- BCDA 0.16
- MACD
- CISS 0.00
- BCDA -0.00
- Stochastic Oscillator
- CISS 1.48
- BCDA 15.91
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).